Jark Böttcher

Jark Böttcher

Auto-generated profile, based on publicly available information

Jark Böttcher

Boehringer Ingelheim RCV, Vienna, Austria

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Nature
Verified
Journal Article
Open access
PDF file
DKDongsung Kim
Dongsung Kim
LHLorenz Herdeis
Lorenz Herdeis
DRDorothea Rudolph
Dorothea Rudolph
YZYulei Zhao
Yulei Zhao
JBJark Böttcher
Jark Böttcher
PLPiro Lito
Piro Lito
KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumour growth in patients1–7. Whether inactive-state selective inhibition can be used to therapeutically target non-G12C KRAS mutants remains under investigation. Here we report the discovery and characterization of a non-covalent inhibitor that binds preferentially and with high affinity to the inactive state of KRAS while sparing NRAS and HRAS. Although limited to only a few amino acids, the evolutionary divergence in the GTPase domain of RAS isoforms was sufficient to impart orthosteric and allosteric constraints for KRAS selectivity. The inhibitor blocked nucleotide exchange to prevent the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. Inhibition of downstream signalling and proliferation was restricted to cancer cells harbouring mutant KRAS, and drug treatment suppressed KRAS mutant tumour growth in mice, without having a detrimental effect on animal weight. Our study suggests that most KRAS oncoproteins cycle between an active state and an inactive state in cancer cells and are dependent on nucleotide exchange for activation. Pan-KRAS inhibitors, such as the one described here, have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.

19 August 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MHMarco H. Hofmann
Marco H. Hofmann
MGMichael Gmachl
Michael Gmachl
JRJuergen Ramharter
Juergen Ramharter
FSFabio Savarese
Fabio Savarese
DGDaniel Gerlach
Daniel Gerlach
NKNorbert Kraut
Norbert Kraut
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non–small cell lung cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream effector pathway, the RAF–MEK–ERK cascade, has shown limited success because of activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important feedback node, represents an effective approach to treat KRAS-driven cancers. We report the discovery of a highly potent, selective, and orally bioavailable small-molecule SOS1 inhibitor, BI-3406, that binds to the catalytic domain of SOS1, thereby preventing the interaction with KRAS. BI-3406 reduces formation of GTP-loaded RAS and limits cellular proliferation of a broad range of KRAS-driven cancers. Importantly, BI-3406 attenuates feedback reactivation induced by MEK inhibitors and thereby enhances sensitivity of KRAS-dependent cancers to MEK inhibition. Combined SOS1 and MEK inhibition represents a novel and effective therapeutic concept to address KRAS-driven tumors. Significance: To date, there are no effective targeted pan-KRAS therapies. In-depth characterization of BI-3406 activity and identification of MEK inhibitors as effective combination partners provide an attractive therapeutic concept for the majority of KRAS-mutant cancers, including those fueled by the most prevalent mutant KRAS oncoproteins, G12D, G12V, G12C, and G13D. See related commentary by Zhao et al., p. 17. This article is highlighted in the In This Issue feature, p. 1

8 July 2019 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JBJark Böttcher
Jark Böttcher
DDDavid Dilworth
David Dilworth
URUlrich Reiser
Ulrich Reiser
RNRalph A. Neumüller
Ralph A. Neumüller
MSMichael Schleicher
Michael Schleicher
DMDarryl B. McConnell
Darryl B. McConnell

22 July 2021 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
DGDaniel B. Grabarczyk
Daniel B. Grabarczyk
OPOlga A. Petrova
Olga A. Petrova
LDLuiza Deszcz
Luiza Deszcz
RKRobert Kurzbauer
Robert Kurzbauer
PMPaul Murphy
Paul Murphy
TCTim Clausen
Tim Clausen

19 March 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAndreas Blum
Andreas Blum
JBJark Böttcher
Jark Böttcher
AHAndreas Heine
Andreas Heine
GKGerhard Klebe
Gerhard Klebe
WDWibke E. Diederich
Wibke E. Diederich

16 November 2020 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
JNJoseph A Newman
Joseph A Newman
AGAngeline E Gavard
Angeline E Gavard
SLSimone Lieb
Simone Lieb
MRMadhwesh C Ravichandran
Madhwesh C Ravichandran
KHKatja Hauer
Katja Hauer
OGOpher Gileadi
Opher Gileadi
Loss of WRN, a DNA repair helicase, was identified as a strong vulnerability of microsatellite instable (MSI) cancers, making WRN a promising drug target. We show that ATP binding and hydrolysis are required for genome integrity and viability of MSI cancer cells. We report a 2.2-Å crystal structure of the WRN helicase core (517–1,093), comprising the two helicase subdomains and winged helix domain but not the HRDC domain or nuclease domains. The structure highlights unusual features. First, an atypical mode of nucleotide binding that results in unusual relative positioning of the two helicase subdomains. Second, an additional β-hairpin in the second helicase subdomain and an unusual helical hairpin in the Zn2+ binding domain. Modelling of the WRN helicase in complex with DNA suggests roles for these features in the binding of alternative DNA structures. NMR analysis shows a weak interaction between the HRDC domain and the helicase core, indicating a possible biological role for this association. Together, this study will facilitate the structure-based development of inhibitors against WRN helicase.